Adjuvant Chemotherapy and the Role of Chemotherapy Resistance Testing for Stage I Non-Small Cell Lung Cancer

This article describes the current clinical application of in vitro chemotherapy resistance testing of patient tumors. The frequency of in vitro chemotherapy resistance in non-small cell lung cancer is extraordinary; however, its clinical relevance remains unproved. Future studies on the use of the extreme drug resistant assay and its integration into clinical trials is justified. The staggering prevalence of non-small cell lung cancer in vitro tumor resistance is reviewed, and the potential role of the extreme drug resistant assay in both clinical and laboratory investigations are discussed.